ריבאבירין טבע 200 מ"ג - Ribavirin teva 200 mg

Ribavirin teva is indicated, in combination with peginterferon alfa-2b or interferon alfa-2b: For the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha therapy but who have subsequently relapse. For the treatment of adult patients with histologically proven chronic hepatitic C, not previously treated, without liver decompensation, with elevated ALT, who are positive for serum HCV-RNA and who have fibrosis or high inflammatory activity. Patients with only portal fibrosis (minimal fibrosis ) should have a high inflammatory score. Ribavirin teva is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b). Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.